Treatment of Cerebral Arteriovenous Malformations With SQUID Liquid Embolic Agent (CHOICE) — CHOICE

Cerebral Arteriovenous Malformation Clinical Trial

Official title:
Treatment of Cerebral Arteriovenous Malformations With SQUID Liquid Embolic Agent - The CHOICE Study A Non-interventional, Prospective, Single-arm, International, Multicenter Study

Status Active, not recruiting

Clinical Trial Summary

The objective of this study is to further establish that SQUID, an alternative liquid embolic agent with specific properties, is a safe and effective alternative in bAVM endovascular treatment strategy available to date. Therefore, the performance of SQUID will be documented and its safety of use will be confirmed in current practice.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Arteriovenous Malformations
Cerebral Arteriovenous Malformation
Congenital Abnormalities
Hemangioma
Intracranial Arteriovenous Malformations

Clinical Trial Details

NCT number	NCT03413852
Study type	Observational [Patient Registry]
Source	Embo-Flüssigkeiten A.G.
Contact
Status	Active, not recruiting
Phase
Start date	May 11, 2018
Completion date	August 2022

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05776706` - Clinical Trial for the Validation of AR Based Neuronavigation System	N/A
Recruiting	`NCT03995823` - Evaluation of Nidus Occlusion After Gamma Knife Radiosurgery of Cerebral Arteriovenous Malformations Using Magnetic Resonance Imaging
Not yet recruiting	`NCT04297033` - Lovastatin for Treatment of Brain Arteriovenous Malformations	Phase 2
Recruiting	`NCT04593966` - Pediatric and Adult Cerebral Arteriovenous Malformation Neurofunctional Outcomes